

Fractalkine/CX3CL1 protects striatal neurons from synergistic morphine and HIV-1 Tat-induced dendritic losses and death

Suzuki *et al.*

RESEARCH ARTICLE

Open Access

Fractalkine/CX₃CL1 protects striatal neurons from synergistic morphine and HIV-1 Tat-induced dendritic losses and death

Masami Suzuki^{1,5}, Nazira El-Hage¹, Shiping Zou², Yun-Kyung Hahn², Mary E Sorrell¹, Jamie L Sturgill³, Daniel H Conrad³, Pamela E Knapp^{1,2,4} and Kurt F Hauser^{1,4*}

Abstract

Background: Fractalkine/CX₃CL1 and its cognate receptor CX₃CR1 are abundantly expressed in the CNS. Fractalkine is an unusual C-X₃-C motif chemokine that is important in neuron-microglial communication, a co-receptor for HIV infection, and can be neuroprotective. To assess the effects of fractalkine on opiate-HIV interactive neurotoxicity, wild-type murine striatal neurons were co-cultured with mixed glia from the striata of wild-type or *Cx3cr1* knockout mice ± HIV-1 Tat and/or morphine. Time-lapse digital images were continuously recorded at 20 min intervals for up to 72 h using computer-aided microscopy to track the same cells repeatedly.

Results: Co-exposure to Tat and morphine caused synergistic increases in neuron death, dendritic pruning, and microglial motility as previously reported. Exogenous fractalkine prevented synergistic Tat and morphine-induced dendritic losses and neuron death even though the inflammatory mediator TNF- α remained significantly elevated. Antibody blockade of CX₃CR1 mimicked the toxic effects of morphine plus Tat, but did not add to their toxicity; while fractalkine failed to protect wild-type neurons co-cultured with *Cx3cr1*^{-/-}-null glia against morphine and Tat toxicity. Exogenous fractalkine also normalized microglial motility, which is elevated by Tat and morphine co-exposure, presumably limiting microglial surveillance that may lead to toxic effects on neurons. Fractalkine immunofluorescence was expressed in neurons and to a lesser extent by other cell types, whereas CX₃CR1 immunoreactivity or GFP fluorescence in cells cultured from the striatum of *Cx3cr1*^{-/-} (*Cx3cr1*^{GFP/GFP}) mice were associated with microglia. Immunoblotting shows that fractalkine levels were unchanged following Tat and/or morphine exposure and there was no increase in released fractalkine as determined by ELISA. By contrast, CX₃CR1 protein levels were markedly downregulated.

Conclusions: The results suggest that deficits in fractalkine-CX₃CR1 signaling contribute to the synergistic neurotoxic effects of opioids and Tat. Importantly, exogenous fractalkine can selectively protect neurons from the injurious effects of chronic opioid-HIV-1 Tat co-exposure, and this suggests a potential therapeutic course for neuroAIDS. Although the cellular mechanisms underlying neuroprotection are not certain, findings that exogenous fractalkine reduces microglial motility and fails to protect neurons co-cultured with *Cx3cr1*^{-/-} mixed glia suggest that fractalkine may act by interfering with toxic microglial-neuron interactions.

Keywords: AIDS, opioid, heroin, drug abuse, glial cell, neuroAIDS, transgenic, cell death, microglia

* Correspondence: kfhauser@vcu.edu

¹Department of Pharmacology and Toxicology, Virginia Commonwealth University School of Medicine, Richmond, VA 23298-0613 USA
Full list of author information is available at the end of the article

Background

Opioid drugs can increase HIV replication and modify HIV pathogenesis through direct interactions with opioid receptor-expressing cells in the immune system [1-5]. We found that opioids can potentiate the neurodegenerative effects of HIV-1 in the central nervous system (CNS) through direct actions at μ -opioid receptor expressing neural cells [6-10], which has support from findings in nonhuman primates [2] and clinical studies [11,12]. The "opioid-cytokine connection" has been proposed to highlight the interrelatedness of the opioid and chemokine systems in HIV disease progression [13,14]. Not only can opioids potentiate the production of chemokines that are known mediators of HIV encephalitis, such as CCL5/RANTES and CCL2/MCP-1 [15-17], but opioid and chemokine systems can undergo mutual cross-desensitization [18,19], and opioid and chemokine receptors may interact directly at the molecular level through the formation of heterodimers [20-22].

Fractalkine (CX₃CL1) [23] and its receptor CX₃CR1 [24] are widely distributed within the nervous system [25,26] in rodents and humans. Unlike other chemokines, fractalkine and its receptor have a unique structural motif (CX₃C) and are the only ligand-receptor pair within the CX₃C subgroup. Accordingly, fractalkine does not cross-react with other chemokine receptors and CX₃CR1 is not activated promiscuously by other chemokines [23,27,28]. Functionally, fractalkine is highly pleiotropic [23,27], acting as both an adhesion molecule and chemoattractant for T cells, NK cells, and macrophages [24,29,30]. CX₃CR1 can also serve as an HIV-1 co-receptor with CD4 [31-33] and is hypothesized to facilitate the spread of HIV-1 infection [34]. Within the nervous system, fractalkine serves a major role as a membrane-tethered neuronal chemokine, while the *Cx3cr1* gene is highly expressed by microglia [26,35]. There are reports suggesting that the receptor is also expressed by neurons and other glial types [25,26,36]. Importantly, emerging evidence indicates that when anchored to the neuronal plasma membrane, fractalkine can modify the actions of microglia. Depending on context, fractalkine can impart life-or-death signals through CX₃CR1. CX₃CR1 engagement can restrict the aggressiveness of activated microglia [37,38], or can protect neurons from exposure to HIV-1 Tat [39] or gp120 through the activation of Akt/PKB [36]. Alternatively, *Cx3cr1* gene deletion has been shown to limit microglial-mediated neuron death in Alzheimer's disease [40].

Fractalkine levels are increased in HIV-associated neurocognitive disorders (HAND) [41-43] and in pediatric patients with HIV-1 encephalitis [39]. Increased fractalkine expression has been proposed as both a mechanism of compensatory neuroprotection as part of a generalized response to lentiviral infections in the CNS [39,44] and

as contributing to the neuronal injury without affecting neuronal death in neuroAIDS [43]. By contrast, other investigators report reductions in fractalkine and CX₃CR1 levels and signaling in neuroAIDS [45]. More recently, fractalkine has been proposed as important for trafficking HIV-infected lymphocytes into the brain [34,42]. Soluble fractalkine attenuates gp120 toxicity in hippocampal neuron cultures in the presence or absence of a glial feeder layer suggesting a direct neuroprotective role [46]. Fractalkine can also modify neuronal signaling through β 1-integrins [47]. Interestingly, Tat possesses an Arg-Gly-Asp (RGD) domain [48] and can bind to α 5 β 1 integrin [49], as well as several other integrins including α v β 3 and α v β 5 [49-51], which suggests at least one possible molecular site where fractalkine and HIV-1 Tat might interact.

Fractalkine injections into the periaqueductal grey attenuate the antinociceptive effects of μ , δ , or κ opioid receptor activation, while fractalkine itself has no effect, suggesting heterologous cross-desensitization between CX₃CR1 and several opioid receptor types [52]. Moreover, intrathecal administration of CX₃CR1 blocking antibodies potentiates morphine analgesia, which was interpreted to result from the blockade of fractalkine-induced increases in IL-1 β and inflammatory pain [53]. Activation of cannabinoid receptors with WIN55,212-2 reduced fractalkine expression by human astrocytes through actions at p38 MAPK that were attenuated by the type 2 cannabinoid receptor antagonist SR144528 [54]. By contrast, fractalkine does not appear to mediate methamphetamine-induced neurotoxicity [55].

These findings prompted us to ascertain whether disruptions in fractalkine-CX₃CR1 signaling might underlie the exaggerated CNS pathology seen with opioid abuse-HIV-1 comorbidity. The data presented herein suggest that morphine and HIV-1 Tat co-exposure may contribute to neuronal injury by downregulating CX₃CR1, and thus interfering with fractalkine signaling. Importantly, soluble fractalkine provided exogenously can rescue neurons from the accelerated injury and death caused by combined morphine and Tat in the presence of wild-type glia.

Results

The distribution of fractalkine immunofluorescence suggested that the chemokine was primarily expressed by neurons, although other cell types occasionally displayed fractalkine immunoreactivity, including subsets of astrocytes as previously reported [25,56]. In untreated control cultures, robust fractalkine immunoreactivity is evident in MAP2-immunopositive neurons (Figure 1A). In contrast to fractalkine, the most intense CX₃CR1 immunofluorescence was punctate and associated with CD11b-immunoreactive microglia (1B; arrows). Preabsorbed fractalkine




Figure 1 Characterization and effects of morphine and/or HIV-1 Tat exposure on bound and soluble fractalkine, and CX₃CR1 levels in mixed striatal neuron-glia cultures. Fractalkine immunofluorescence was readily co-localized in MAP2-positive neuron cell bodies and dendrites (A), while a majority of the CX₃CR1 immunoreactive cells were CD11b-positive microglia (B); scale bar = 15 μ m. Fractalkine derived from neuron-glia co-cultures presented a prominent band at approximately 95-kDa (C). This is slightly higher than the non-glycosylated, recombinant fractalkine (rFKN) control protein detected at 90-kDa; 0.1 μ g and 0.025 μ g fractalkine (FKN) were loaded onto the left-hand lanes. The relative abundance of either variant appeared to be unaffected by morphine (Morph) and/or Tat treatment at 24 h (C); n = 3 experiments. The amount of fractalkine released into the culture medium was unaffected following 2 h of morphine and/or Tat exposure (D); the limit of fractalkine detection by ELISA was 320 pg/ml (standard curve in D); n = 3 experiments. Unlike fractalkine, treatment with morphine and Tat together significantly reduced CX₃CR1 levels (~47-kDa) at 24 h, but not 6 h or 12 h, compared to vehicle-treated controls (E) (**P* < 0.02 vs. vehicle-treated controls; Kruskal-Wallis ANOVA and nonparametric post hoc tests), while CX₃CR1 levels were unaffected by exposure to morphine or Tat alone (E); fractalkine and CX₃CR1 levels were normalized to actin (~43-kDa bands in C,E) in immunoblots; n = 6 experiments.

controls displayed no specific immunoreactivity (not shown).

Effect of Tat and morphine on levels of fractalkine and CX₃CR1

To detect fractalkine by immunoblot, we used an antibody directed against the N-terminal chemokine domain

(AF472; R&D Systems, Minneapolis, MN). In immunoblots of whole-cell lysates, which include neurons, astroglia and microglia, fractalkine presented as an approximately 95-kDa band (Figure 1C). Recombinant, non-glycosylated fractalkine, which served as a positive-control, resulted in a 90-kDa band [57]. The relative abundance of either variant appeared to be unaffected

by morphine and/or Tat treatment at 24 h (Figure 1C). The antibody does not recognize the residual approximately 20 kDa C-terminal tail that anchors fractalkine to the cell membrane.

To assess whether morphine and/or Tat treatment affected fractalkine shedding, the amount of released fractalkine in the conditioned medium of mixed neuronal cultures was analyzed by ELISA at 2 h following morphine and/or Tat exposure (Figure 1D). The limit of detection of the fractalkine assay was 320 pg/ml. Soluble fractalkine was detected in the medium of vehicle-treated control cultures (2.50 ± 0.15 ng/ml), suggesting that fractalkine is constitutively cleaved and released at relatively high levels. The proportion of neurons in our cultures were purposely low relative to numbers of glia (1:20 ratio) to mimic neuron:glia ratios in vivo. Both astroglia and neurons express fractalkine [25,36,41,54,56,58]. Despite reports that a vast majority of fractalkine originates from neurons (especially when they are co-cultured with glia [59]), the neurons in our cultures are vastly outnumbered by astroglia. Thus, while relatively constant amounts of fractalkine are released irrespective of morphine and/or Tat exposure, it is difficult to know the neuronal versus astroglial contribution or the extent to which more subtle, subcellular changes in neuronal release might be masked. Thus, the results are inconclusive regarding whether changes in fractalkine shedding by neurons underlie synergistic morphine-Tat neurotoxicity (Figure 1C,D), and additional study is warranted.

To explore possible morphine and/or Tat-induced alterations in fractalkine receptor expression by microglia, CX₃CR1 was examined by immunoblotting. In mixed striatal cultures, CX₃CR1 was detected as a major band at about 47 kDa, which coincides with its expression pattern in other cell types [29]. Compared to vehicle-treated controls, CX₃CR1 levels were diminished, although not significantly, in either morphine or Tat-exposed cultures at 24 h (Figure 1E). Treatment with morphine and Tat together did significantly reduce CX₃CR1 levels by about 40% compared to controls, but not compared to cultures treated with morphine or Tat alone. The findings show that, in combination, morphine and Tat may cumulatively downregulate CX₃CR1 levels (Figure 1E). CX₃CR1 expression was largely restricted to microglia in our striatal cultures. Accordingly, the marked decline in CX₃CR1 levels with morphine and Tat co-exposure is presumed to represent a preferential microglial response. It is also noteworthy that reductions in CX₃CR1 levels occurred despite previous findings that Tat ($14.7 \pm 1.3\%$) or morphine plus Tat ($13.7 \pm 1.7\%$) treatment significantly increases the proportion of microglia in mixed-glia cultures from striatum compared to controls ($8.8 \pm 0.6\%$) [60].

Neurotoxicity

Analyzing the response of individual neurons throughout the experiment eliminates inter-subject variability and permits subtle treatment effects to be revealed [61,62]. Computer-aided tracking permits large numbers of neurons (and glia) to be followed and consistently assessed over time, which greatly facilitates and improves the sensitivity of the assay (Figure 2A-E). Although Tat alone did not cause significant neurotoxicity relative to controls at individual times tested, there was a significant interaction effect ($^{\$}P < 0.03$; Tat \times time vs. Control \times time) indicating a significantly greater decline in the rate of survival of Tat-treated neurons compared to controls from 0 h to 48 h (Figure 2D). This suggests that even greater proportions of neurons are likely to be lost with more prolonged Tat exposure, as observed previously [62]. Alternatively, combined exposure to Tat and morphine caused interactive neuron losses (Figure 2C-D), similar to the accelerated synergistic neuron death described previously with morphine and Tat co-administration [10] ($*P < 0.05$) (Figure 2D). These interactive effects have previously been shown to be selective for Tat, and do not occur with either denatured or mutant forms of the viral protein [10,61].

Fractalkine rescues neurons from synergistic morphine and Tat neurotoxicity

Compared to vehicle controls, neuron viability was unaffected by treatment with fractalkine (1 μ g/ml) alone (Figure 2D). By contrast, co-exposure to morphine (500 nM) and Tat (100 nM) significantly enhanced neuron losses during the 48 h exposure period (Figure 2C,D), while the synergistic neurotoxicity was entirely prevented by addition of exogenous fractalkine (1 μ g/ml) to the medium (Figure 2B,D). Incubation with CX₃CR1 blocking antibodies alone was also neurotoxic, at levels indistinguishable from the combined effects of morphine and Tat (Figure 2E). However, when anti-CX₃CR1 antibodies were co-incubated with morphine and Tat, there was no additional neurotoxicity (Figure 2E). This suggests that neuron death is enhanced when protective signaling through CX₃CR1 is attenuated, either by reducing levels of CX₃CR1 (as seen after 24 h with morphine and Tat co-exposure; Figure 1E), or by physically limiting CX₃CL1-CX₃CR1 interactions through immunoblockade (Figure 2E). Combining CX₃CR1 blockade with morphine and Tat exposure does not increase the amount of neuron death seen with morphine and Tat co-administration alone, perhaps indicating that CX₃CR1 function is already maximally reduced in morphine plus Tat exposed cells. While Tat or morphine by themselves did not significantly reduce CX₃CR1 levels, the trend towards reduced expression (Figure 1E) suggests that this might occur with more prolonged exposure.




Figure 2 Effects of fractalkine on morphine and/or HIV-1 Tat-induced toxicity was repeatedly tracked in individual striatal neurons (A-E).

A within-subjects design and computer-assisted, time-lapse tracking of individual neurons is used to compare the survival of the same neuron before and at 20 min intervals throughout treatments (A-E). Thriving neurons are evident in control (A; neurons 1-3) or morphine (Morph) + Tat-treated cultures co-administered fractalkine (B; neurons 1-4) at 48 h. By contrast, increased neurodegeneration and death was apparent with morphine plus Tat exposure (C). Neuron death is often preceded by the systematic degeneration of neurites and fragmentation of the cell body (Tat + morphine treatment; arrowheads, neuron 1), while death per se occurs precipitously; denoted here by fragmentation of the cell body and some loss of birefringence (arrow, neuron 1; 44 h and 48 h) (C). Some individual microglia that were tracked are encircled in red, orange, and yellow, respectively (arrowheads indicate prior movement); there was close association of microglia with the dying (1) and surviving (2) neuron (not all microglia in the fields are encircled) (C). Neuron death has been confirmed using other viability markers (see text). Many neurons remain viable despite morphine and Tat co-exposure (e.g., neuron 2); some surrounding cells, including astroglia, immature glial precursors and microglia, can display sporadic movement; scale bars = 20 μ m. While Tat alone did not cause significant neurotoxicity relative to controls by 48 h [61,62]; there was a significant interaction when overall neuron losses were compared in Tat versus non-Tat vehicle-treated cultures ($^5P < 0.03$; Tat \times time vs. Vehicle-control \times time). Compared to controls or exposure to fractalkine alone, combined morphine and Tat (Morph+Tat) treatment increased neuronal death at 48 h (D) ($^*P < 0.05$ vs. controls). Exogenous fractalkine (1 μ g/ml) (red markers and connecting lines) prevented the accelerated neuronal death caused by combined Morph+Tat ($^{\#}P < 0.05$ vs. Morph+Tat) (D). By contrast, CX₃CR1 immunoblockade (blue markers and connecting lines) by itself caused significant neurotoxicity that was indistinguishable from the combined effects of Morph+Tat (E) ($^*P < 0.05$ vs. controls). Moreover, when CX₃CR1 blockade was combined with Morph+Tat, there were no additive neuron losses (E). The findings suggest a critical role for fractalkine-CX₃CR1 signalling in potentiating the toxic effects of opioids in Tat-exposed neurons; data are the mean number of surviving neurons (compared to pretreatment numbers) \pm SEM from $n = 3-6$ experiments; wild-type (WT) neurons and mixed glia; antibodies (Ab); scale bar = 20 μ m.

Selectivity of fractalkine's neuroprotective action

To explore the selectivity of fractalkine's neuroprotective effect and to begin to discern whether fractalkine is acting via neuronal or glial receptors, *Cx3cr1*^{-/-} (*Cx3cr1*^{GFP/GFP}) mice were obtained and mixed glial cultures established from their striata. Prior to starting in vitro studies, *Cx3cr1*^{-/-} mice were examined histologically. In the striatum, the predominant GFP⁺ cell type was microglia, which were intensely fluorescent (Figure 3A,B). The intensely fluorescent GFP⁺ cells readily co-localized with ionized calcium binding adaptor molecule 1 (Iba-1) (Figure 3C), as previously reported for this *Cx3cr1*^{-/-} mouse strain [38], and high levels of GFP fluorescence were retained by microglia, but not astrocytes, in mixed glial cultures (Figure 3D) (Table 1).

In cell cultures, *Cx3cr1*-null microglia differed considerably from their wild type counterparts. The proportion of microglia:astrocytes was over 3-fold greater than that consistently seen in wild-type mixed-glial cultures [60], despite identical culture conditions in the present study. When wild-type neurons were co-cultured with *Cx3cr1*^{-/-} glia, baseline levels of neuron death (41.0 ± 3.2% surviving) appeared to be much greater than losses typically seen in the presence of wild-type glia (Figure 3E, upper panel; 77.7 ± 2.7% surviving). Fundamental differences in cellular makeup and behavior of mixed-glia cultures from *Cx3cr1*-null compared to wild type cultures, even prior to the addition of neurons, negated the validity of direct "side-by-side" comparisons of neuron survival in co-culture with wild-type versus *Cx3cr1*-null mixed glia. However, in our extensive experience with this co-culture model [60,63,64], neuron survival rates in control cultures are always between 75-90% at 48 h. The greater apparent neuron losses might be related to the > 300% increase in microglial numbers observed in *Cx3cr1*^{-/-} cultures (Table 1). Importantly, the relative neuroprotective effects of fractalkine (1 µg/ml) against morphine + Tat neurotoxicity were abolished when wild-type neurons were co-cultured with *Cx3cr1*^{-/-} mixed glia (Figure 3E), suggesting fractalkine protection was mediated by CX₃CR1-expressing microglia. Although there were no differences in survival between vehicle + control versus fractalkine + control neurons, there is some possibility that fractalkine enhances baseline neuron survival in the *Cx3cr1*^{-/-} glial co-cultures. This is suggested by significant differences only at 48 h between Tat + fractalkine versus control + fractalkine survival ([§]*P* < 0.05), even though survival does not differ within control ± fractalkine or Tat ± fractalkine treatments. A similar inconsistency is observed only at 48 h with morphine treatments ([§]*P* < 0.05). The inconsistencies may result from some residual actions in the wild-type cells since even the most highly enriched neuron cultures contain some (< 1%) glia.

Effect of fractalkine on microglial motility

Amoeboid migration as seen in leukocytes is an active process requiring actin polymerization, which is typically signaled through small GTPases in response to extracellular stimuli [65]. The chemotactic targeting of infected or injured cells is a critical aspect of microglial function as immune effectors. Accordingly, we investigated the effects of fractalkine on microglial movement. The identity of individual activated microglia was readily discerned using phase-contrast microscopy by criteria described in the Methods, and the identity of individual cells could be interrogated using immunofluorescent-tagged antibodies against surface antigens such as Iba-1 shown in Figure 4A-B. Movement differed among individual microglia (Figures 4A & 5A-C), though the average movement within a population was quite reproducible and highly sensitive to extracellular signals (Figure 5A-D). We measured the linear movement of individual microglia each hour from 0 to 12 h after treatment. Vehicle-treated microglia migrated an average of 17 µm/h during this time and motility in microglia that were not exposed to Tat and/or morphine was unaffected by exogenous fractalkine (Figure 5D). Treatment with morphine or Tat alone tended to increase microglial movement, but the effect was not significant over 12 h. By contrast, continuous exposure to combined morphine and Tat significantly increased the movement of microglia to ~30 µm/h. In this case, fractalkine (1 µg/ml) significantly inhibited the increase in microglial migration rate, bringing it back to pretreatment levels (~17 µm/h) (Figure 5D). The fact that fractalkine did not reduce baseline motility, and did not reduce motility increases due to Tat+ morphine to below pretreatment values, suggests that motility is only partially controlled by fractalkine and that alternative signals [66,67] maintain baseline rates of movement.

Effects of morphine and/or Tat ± fractalkine on dendrite length

There was a tendency for morphine or Tat alone to reduce dendrite length following 72 h exposure (Figure 6A-E), but the effects were not significant (Figure 6E). By contrast, morphine and Tat in combination caused significant reductions in dendritic complexity in MAP2-immunoreactive striatal neurons after 72 h (Figure 6B,E). Importantly, concurrent exposure to exogenous fractalkine (1 µg/ml) prevented the dendritic pruning caused by morphine and Tat co-exposure (Figure 6D,E).

Effects of fractalkine on the production of TNF-α

TNF-α has been shown to play a central role in initiating inflammatory cascades in Tat exposed astroglia and microglia [15,68,69]. ELISA was performed at 12 h following morphine and/or Tat exposure to determine





Figure 3 Studies with *Cx3cr1*^{-/-} mice: Fluorescent images and effects of *Cx3cr1*^{-/-} glia on fractalkine-mediated neuroprotection. Images of the striatum (A-C) and of mixed glial cultures (D) from *Cx3cr1*^{-/-} mouse striata. Microglia within the striatum of *Cx3cr1*^{-/-} (*Cx3cr1*^{GFP/GFP}) mice fluoresce green (A,B) and are Iba-1 immunoreactive (C); Hoechst counterstained nuclei (blue); scale bars = 50 μ m (A) and 10 μ m (B,C). Robust GFP expression is maintained when the cells are placed into culture (D). As can be appreciated from the Hoechst stain, the CX₃CR1-expressing population is significant although the majority of the cells in the culture lack CX₃CR1. The loss of CX₃CR1 on glia has a dramatic effect on the ability of fractalkine to protect morphine and Tat-treated striatal neurons (E). Neurons from the striata of wild-type mice were plated onto mixed glia prepared from *Cx3cr1*^{-/-} mouse striata and followed over 48 h using our standard paradigm. In general, wild-type neurons co-cultured with *Cx3cr1*^{-/-} glia appeared to be less viable than with wild-type glia (upper panel; compare gray and black dotted lines); however, these groups were not compared statistically since the experiments were not run concurrently. The neuroprotective effects of fractalkine (CX₃CL1; 1 μ g/ml) are abolished when wild-type neurons are co-cultured with *Cx3cr1*^{-/-} mixed glia. Under these conditions, fractalkine no longer protects neurons from combined morphine and Tat exposure (E, lower panel; **P* < 0.05 vs. vehicle- or fractalkine-treated controls). There were no differences in survival between controls \pm fractalkine. Addition of fractalkine did not change the toxicity of morphine, Tat, or morphine + Tat treatments. There is, however, some possibility that fractalkine enhances baseline neuron survival in the *Cx3cr1*^{-/-} glial co-cultures. This was indicated by significant differences only at 48 h between Tat + fractalkine versus control + fractalkine survival (^S*P* < 0.05), even though survival did not differ when comparing vehicle + control vs. fractalkine + control or vehicle + Tat vs. fractalkine + Tat treatments. A similar inconsistency was observed only at 48 h with morphine treatments (^S*P* < 0.05).


Table 1 Effects of morphine and/or HIV-1 Tat exposure ± fractalkine on the percentage of microglia in mixed-glia cultures from striata of *Cx3cr1*^{-/-} (*Cx3cr1*^{GFP/GFP}) mice (†).

	Control	Morphine	Tat	Morphine + Tat
Microglia (%) (<i>Cx3cr1</i> ^{-/-} mixed glia)	31.0 ± 6.7 [§]	26.7 ± 2.5	26.7 ± 5.1	34.9 ± 1.6
Microglia (%) (<i>Cx3cr1</i> ^{-/-} mixed glia + fractalkine)	25.8 ± 2.3	25.8 ± 6.7	25.5 ± 4.0	30.9 ± 0.7

† No significant effects of morphine and/or HIV-1 Tat ± fractalkine (1 µg/ml) exposure on the proportion of GFP⁺ microglia were noted; effects were compared using 2-way ANOVA.

§ The proportion of microglia in mixed glial cultures from *Cx3cr1*^{-/-} mice was much greater than percentages seen in equivalent striatal cultures from wild-type mice (e.g., 8.8 ± 0.6% Iba-1⁺ microglia in control cultures) determined as part of another study [60].





whether fractalkine might be protecting neurons by reducing TNF- α levels in our cultures. As shown before for striatal astroglia [17,70], Tat \pm morphine significantly increased TNF- α production by these mixed neuronal-glia cultures (Figure 7); TNF- α production was unaffected by fractalkine or immunoblockade of CX₃CR1, although there was a trend toward increased TNF- α release in control and morphine-treated cultures with CX₃CR1 blockade (Figure 7). Thus, fractalkine-mediated protection occurs despite a sustained TNF- α -induced inflammatory signal.

Discussion

Our results indicate that exogenous fractalkine completely blocks the synergistic neurotoxicity caused by combined morphine and Tat exposure. This appears to be mediated by CX₃CR1 expressed by microglia, since fractalkine

neuroprotection is abolished when wild-type neurons are co-cultured with *Cx3cr1*-null mixed glia and because CX₃CR1 is almost exclusively expressed by microglia in these cultures. Moreover, the neuroprotection is accompanied by a marked reduction in microglial motility that was otherwise significantly increased by morphine and Tat co-exposure. Although exogenous fractalkine is able to (i) rescue opiate and HIV-1 Tat treated neurons and (ii) limit microglial motility, the present study does not fully discern the cellular sites or mechanisms of fractalkine's protective action. Thus, while the neuroprotective effects of fractalkine are presumed to be due to direct actions on striatal microglia in the present study, we cannot completely rule out the possibility that fractalkine can act via alternative cell types in other brain regions [36,71].

Because the neurotoxic effects of HIV Tat and opiates were negated by exogenous fractalkine, we questioned






Figure 6 Effects of fractalkine or immunoneutralizing anti-CX₃CR1 antibodies on morphine and/or Tat-induced degeneration of MAP2-immunoreactive dendrites of striatal neurons at 72 h (A-E). Compared to vehicle controls (Con) (A), morphine and Tat (Morph+Tat) (B) caused significant reductions in dendritic length (**P* < 0.05 vs. vehicle controls) (E). Fractalkine prevented Morph+Tat-induced dendritic pruning ([#]*P* < 0.05 vs. Morph+Tat) (D,E), but by itself had no effect (C,E). Data in E are mean dendrite length (μm) ± SEM from n = 4 experiments; scale bar = 20 μm.



whether fractalkine-CX₃CR1 signaling might be disrupted in neurons and/or glia exposed to opiates and Tat and began to address this question in a preliminary fashion. A disruption in fractalkine-CX₃CR1 signaling by opiate-HIV protein exposure would parallel evidence from a variety of other CNS disorders where fractalkine-CX₃CR1 interfacing appears to be altered, including Parkinson's and Alzheimer's diseases, as well as in HIV dementia [40,44,72]. Close associations between fractalkine-expressing neurons and CX₃CR1-positive microglia have been described in the CNS of pediatric patients with HIV-1 encephalitis [39], but expression levels of either the fractalkine ligand or receptor were not ascertained. More recently, CX₃CR1-directed pruning of aberrant synapses was found to be necessary for normal CNS maturation [73]. *Cx3cr1*-null mice retained large numbers of immature synapses displaying deficits in neuronal function and behavior [73]. Assuming restricted fractalkine-CX₃CR1 interfacing, an attenuated signal might originate from a decline in fractalkine, its receptor or both.

Fractalkine has multiple neuroprotective, cell-adhesion, and chemotactic functions through actions as both

a bound and a diffusible factor [37,38]. This complexity adds to the challenge of understanding fractalkine-CX₃CR1 actions. Membrane-bound fractalkine can function as an adhesion molecule for cells that express CX₃CR1, while proteolytically released fractalkine functions as a more typical soluble chemokine [30]. Fractalkine is reportedly cleaved by ADAM (a disintegrin and metalloproteinase) 10 and perhaps ADAM17 (TNF-α converting enzyme or TACE) [57,74-76]. Cleavage results in soluble 60-85-kDa fractalkine (depending on residual glycosylation) and a ~20-kDa transmembrane C-terminal fragment that remains anchored to the cell membrane [57]. Once shed, fractalkine undergoes tissue-specific processing, which may contribute to localized immune responses [77,78]. Soluble fractalkine limits microglial neurotoxicity [30,36,38], as seen in the present study, and sustained fractalkine release may be necessary for continued protection from microglial surveillance [59].

In control cultures, the presence of secreted fractalkine in the medium suggests that bound fractalkine is constitutively cleaved and tonically released by ADAM10 [74]. ADAM10 is inducible and is acutely sensitive to increases in [Ca²⁺]_i caused by excitotoxic levels of glutamate [76]. Despite the potential for dynamic changes in fractalkine release, the concept that morphine ± HIV-1 Tat exposure neurotoxicity might be mediated by altered fractalkine production or shedding is not supported by our findings. The relative abundance of bound (immunoblots) and released, soluble fractalkine (ELISA) was unaffected by morphine or Tat treatments. Nevertheless, additional studies are needed to address this question systematically. Although neurons reportedly shed greater amounts of fractalkine than astroglia [59], because astroglia outnumber neurons in our cultures by ~20-fold, the relative contribution of each to the fractalkine pool is uncertain and a potentially unique response by neurons may be overshadowed.

There is less agreement regarding how CX₃CR1 levels affect neuron survival or function. CX₃CR1 is most often reported as a ~50-kDa protein [79], which is in agreement with the present findings, although cell-type specific CX₃CR1 isoforms of ~40 kDa have been reported [80] that likely result from alternative splicing and/or differences in CX₃CR1 glycosylation [79]. The cellular distribution and intensity of CX₃CR1 immunoreactivity and GFP in *Cx3cr1*-null mice indicated that the receptor was expressed by microglia at high levels in striatum (Figures 1B & 3A-D). In cultures of mixed glia lacking the *Cx3cr1* gene, we found the proportion of microglia:astroglia was much higher. Moreover, when wild-type neurons were co-cultured with *Cx3cr1*-null glia, the background rate of neuron death was much greater than with wild-type glia—even under identical culture conditions. This suggests

fundamental differences between the function of *Cx3cr1*-deleted and wild-type microglia. The neuroprotective effects of fractalkine were lost when morphine and Tat-co-exposed wild-type neurons were cultured with *Cx3cr1*-knockout glia. This strongly infers that fractalkine protects neurons through interactions with microglial CX₃CR1, although inherent differences in the cytotoxicity of *Cx3cr1*-deleted microglia may represent a confound. Unlike fractalkine, CX₃CR1 levels showed a classic down-regulation after 24 h continuous exposure to combined morphine and Tat. The reduction appeared to be additive since morphine and Tat by themselves both produced modest, but not significant, reductions in CX₃CR1 levels. Antibody blockade of CX₃CR1 caused toxicity equal to Tat and morphine co-exposure, while *Cx3cr1* gene deletion from glia appeared to increase baseline levels of neuron death even in control cultures (see Figure 3E).

Microglial chemotaxis, activation, and overactivation are regulated by hierarchical signals that are critically important in the inactivation/removal of pathogens [81]. Unchecked, microglial overactivation may cause bystander cytotoxicity [81-83]; yet, microglial activation appears reversible [81], suggesting an opportunity to allay the deleterious consequences of overactivation. HIV-1 or opioid exposure can trigger key events underlying microglial (and astroglial) activation including increases in oxyradicals [84], glutamate secretion [85], and the production of proinflammatory cytokines and chemokines [15-17,86]; while many of these deleterious signals can be attenuated by fractalkine/CX₃CR1 activation [30,38,44,87,88]. In fact, increases in fractalkine may be a protective response in CNS injury and some diseases [89,90]. Our results suggest that CX₃CR1 signaling can short-circuit key aspects of microglial overactivation caused by morphine and Tat, thereby enhancing neuron survival and function.

The above findings suggest that CX₃CR1 signaling is fundamentally important for microglial function. In fact, it has been suggested that deleting the *Cx3cr1* gene dysregulates so many aspects of microglial function (including functions regulating both protective and toxic bystander effects) that it may no longer be possible to correctly interpret the role of fractalkine-CX₃CR1 interactions in a particular situation [30,37,38]. For example, neuron death was mitigated by *Cx3cr1* deletion in models of Alzheimer's disease and ischemia [40,91]. By contrast, neurotoxicity was exacerbated by *Cx3cr1* deletion in three other neuroinflammatory models [38], while CX₃CR1 is essential for normal synaptic pruning during maturation [73]. Thus, the consequences of fractalkine-CX₃CR1 signaling appear to be complex, varying depending on the particular disease, the brain region studied, and context. Clearly, the present findings suggest that CX₃CR1 regulates critical microglial functions, and reductions in CX₃CR1 levels coincide with basic imbalances in astroglial:microglial

numerical matching and marked reductions in striatal neuron viability.

Notwithstanding its chemotactic and surveillance functions [28,37], fractalkine is reported to limit cytotoxicity by reducing microglial activation and killing [30,37,38]. HIV-1 Tat induces the production of chemokines that increase microglial chemotaxis including CCL2/MCP-1 [86,92] and CCL5/RANTES [15,16]. In the present study, although exogenous fractalkine completely blocked the increase in microglial motility caused by combined morphine and Tat exposure, it had no effect on baseline movement. Moreover, fractalkine negated the synergistic morphine and Tat neurotoxicity despite elevated levels of TNF- α in the culture medium. Assuming fractalkine may attenuate microglial activation through an alternative mechanism, we examined 3-nitrotyrosine and nitrite production, which are reactive nitrogen byproducts that are highly sensitive to morphine and HIV-1 Tat interactions [60,93]. In preliminary studies, we found that morphine + Tat-induced increases in both nitrosative byproducts were entirely unaffected by exogenous fractalkine (1 μ g/ml) at 24 h or 48 h (data not shown). Additional studies are needed to assess whether fractalkine might affect other key redox and proinflammatory pathways in microglia before suggesting that fractalkine's actions are restricted to microglial motility or surveillance. Since nitrosative stress and TNF- α production lie upstream of, and instigate, multiple inflammatory signaling events, we propose that fractalkine selectively overrides key aspects of microglia activation at relatively late stages in the inflammatory process to prevent cytotoxic killing. If this assumption is correct the findings have considerable therapeutic implications for chronic substance abuse and HIV-1 comorbidity.

Conclusions

Fractalkine-CX₃CR1 signaling in striatal neuron-glia co-cultures appears to be compromised by opioid drug and HIV-1 co-exposure, and this may contribute to increased neuronal injury. Levels of CX₃CR1 are reduced by morphine and Tat co-exposure, and the addition of exogenous fractalkine completely prevents the interactive neurotoxicity. Since CX₃CR1 is expressed almost exclusively by microglia in the mixed-glia cultures, this suggests that fractalkine protects neurons against morphine and Tat co-exposure through direct actions on microglia. In glia from mice lacking the *Cx3cr1* gene the proportion of microglia:astroglia was much higher and background rates of neuron death were greater than wild-type glia even under identical culture conditions, suggesting fundamental differences between the function of *Cx3cr1*-null and wild-type microglia. Despite these inherent differences, the neuroprotective effects of fractalkine were lost when morphine and Tat-co-exposed wild-type neurons are cultured with glia lacking the *Cx3cr1* gene further

inferring fractalkine-CX₃CR1 interactions as protective. Thus, fractalkine may have considerable therapeutic potential in limiting inflammation, microglial overactivation, and neuronal injury with opioid abuse and/or neuroAIDS.

Methods

Animals

ICR (CD-1) mice were purchased from Charles River Inc. (Charles River, MA), while *Cx3cr1*^{-/-} (*Cx3cr1*^{GFP/GFP}) mice [26] on a C57BL/6J genetic background were obtained from Jackson Laboratory (Bar Harbor, ME) and originally engineered by Dr. Dan Littman (Skirball Institute, New York University School of Medicine, NY, NY). In all experiments, mice were anesthetized and/or euthanized in accordance with NIH and local Virginia Commonwealth University IACUC guidelines, which minimize the number of mice used and their possible discomfort.

Mixed-glia cultures

Mixed glial (astroglia and microglia) cultures were prepared from neonatal (P0-P1) wild-type ICR or *Cx3cr1*^{-/-} mouse striata (Charles River) as previously described [70]. Striata were dissected, minced, and incubated with 10 ml trypsin (2.5 mg/ml) and DNase (0.015 mg/ml) in serum free medium (30 min, 37°C). Tissue was triturated, resuspended in 10 ml culture medium with 10% fetal bovine serum, filtered through 135 µm and then 45-µm pore nylon mesh, prior to plating (~2.5 × 10⁵ cells/cm²) on poly-D-lysine coated coverslips. After mixed glia from wild-type or *Cx3cr1*^{-/-} mice were cultured approximately 6-8 days *in vitro* they were used as a bedlayer for co-culturing neurons. Despite functional deletion of *Cx3cr1*, the null gene was engineered to continue to express GFP as a marker [see [26]]. The proportion of Hoechst⁺ cells in the mixed glial cultures that were GFP⁺ was determined following 48 h of continuous vehicle, morphine, HIV-1 Tat, or morphine plus Tat exposure (Table 1). At least 300-500 cells were counted per treatment group in each experiment (N = 1). Experiments were repeated 3 times and data presented as the mean ± the SEM (N = 3).

Neuronal culture or co-culture with mixed glia from wild-type or *Cx3cr1*^{-/-} (*Cx3cr1*^{GFP/GFP}) mice

Striatal neurons were prepared from wild-type E15-E16 ICR (CD-1) mouse embryos. Striata were dissected, minced, and incubated with 10 ml trypsin (2.5 mg/ml) and DNase (0.015 mg/ml) in Neurobasal medium (Invitrogen, Carlsbad, CA) with 25 µM glutamate (30 min, 37°C). Tissue was triturated, resuspended in 10 ml medium, and cells filtered twice through 70 µm pore nylon mesh. Isolated wild-type neurons were (i) plated alone on poly-D-lysine coated coverslips or (ii) co-cultured directly on a

bedlayer of mixed glia derived from wild type or *Cx3cr1*^{-/-} mice. Neuron cultures and neuron-glia co-cultures were similarly maintained in Neurobasal medium supplemented with B27, 0.5 mM L-glutamine, 0.025 mM glutamate, and allowed to mature for about 1 wk prior to the start of the experiments.

Assessment of neuron viability

Time-lapse digital images were recorded at 20 min intervals for 48 h using a microscope (Zeiss Axio Observer Z.1) and automated, computer-controlled (AxioVision 4.6; Mark&Find, MosaiX, and Time Lapse software) stage encoder with environmental control (37°C, 95% humidity, 5% CO₂; PeCon Instruments, Houston, TX), to repeatedly track the same neurons [64]. Repeated measures ANOVA was used to compare treatment effects on the same neuron at the onset and throughout the experiment (Statistica; StatSoft, Tulsa, OK). In each experiment, treatments were distributed across cells pooled from the same pups. Approximately 50 healthy neurons with well defined dendritic and axonal arbors were identified using phase-contrast microscopy (40× magnification) within individual culture wells in each experiment prior to treatment (0 h) (Figure 2A-C). The effects of opioids and/or HIV-1 Tat ± fractalkine or CX₃CR1 immunoblockade ± mixed glia from wild-type or *Cx3cr1*^{-/-} mice on neuron survival was determined at 4 h intervals and averaged per culture well/treatment (n = 1). Neuron injury and death was monitored in individual cells and defined by rigorous criteria, which included dendritic pruning, dissolution of the Nissl substance, transient cytoplasmic swelling and vacuolization, nuclear damage, and eventual destruction of the cell body [61,63,64]. In some cases, neuron death was confirmed by viability markers such as ethidium homodimer, ethidium monoazide, or trypan blue (not shown); however, these markers all possess some inherent cytotoxicity with prolonged exposure, which precludes their use to monitor cells continuously. The effect of each treatment on neuron survival was analyzed statistically at 4 h intervals using repeated measures ANOVA from n = 5-6 experiments (200-300 neurons in total per treatment) and reported as the mean percentage of surviving neurons, relative to pre-treatment values ± the standard error of the mean (SEM), but designated as “% of control” for simplicity.

Experimental treatments

Cultures were continuously treated with recombinant Tat₁₋₈₆ (100 nM; from HIV-1_{IIIB} strain, ImmunoDiagnostics, Woburn, MA), morphine sulfate (500 nM; Sigma, St. Louis, MO), full-length recombinant mouse fractalkine (1 µg/ml) (R&D Systems, Inc., Minneapolis, MN; catalog no. 472-FF/CF), and/or anti-CX₃CR1 antibodies lacking azide (Torrey Pines Biolabs, East Orange, NJ).

Immunocytochemistry

Cell cultures were fixed for 15 min in 3% paraformaldehyde in phosphate buffer (pH 7.2 at 4°C), permeabilized in 0.1% Triton-X 100, and rinsed 3 × 20 min in PBS, pH 7.2. Cultures were incubated in diluted primary antiserum on an orbital shaker (40-60 rpm) overnight at 4°C in PBS, pH 7.2 with 1% crystalline grade BSA (Calbiochem/EMD Chemicals, Gibbstown, NJ) and 0.1% Triton-X 100. Rabbit anti-mouse fractalkine (1:100; catalog no. TP233; Torrey Pines Biolabs) or rabbit anti-rat CX₃CR1 (1:100; catalog TP501; Torrey Pines Biolabs) antigenicity was co-localized with antibodies to MAP2 a/b (1:200; catalog MAB 378; Chemicon, Temecula, CA), glial fibrillary acidic protein (GFAP) to detect astroglia (1:200; Chemicon), or CD11b (1:100; catalog No. MAB1124; R&D Systems) to identify microglia. MAP2, GFAP, and CD11b antigenicity were detected using appropriate secondary antibodies conjugated to Alexa 488 (1:500 dilution; Molecular Probes, Eugene, OR) or Cy3 (1:250 dilution; Jackson ImmunoResearch, West Grove, PA). Cells were counterstained with Hoechst 33342 (1 µg/ml), which labels all cell nuclei blue. A rabbit polyclonal antibody against Iba-1 (Wako Chemicals USA, Richmond, VA, 1:500) and an anti-rabbit secondary antibody conjugated to Alexa 594 were also used to detect microglia and ascertain the extent of Iba-1-GFP overlap in mixed glial cultures from *Cx3cr1*^{-/-} mice. Cultures were rinsed and mounted in Prolong Antifade compound (Molecular Probes). For measurements of dendrite length, neuron cell bodies and dendrites were labeled using anti-MAP2a/b antibodies (1:200; Chemicon) and secondary antibodies conjugated to horseradish peroxidase and visualized using diaminobenzidine. Preabsorbed fractalkine antibody controls consisted of rabbit anti-murine fractalkine antibody (R&D Systems) IgG preabsorbed with 25 µg/ml of the recombinant fractalkine peptide epitope used for antibody production for 1 h at 37°C, 5% CO₂ and in high humidity.

Fluorescence microscopy

Fluorescent images were obtained using Zeiss Axio Observer Z.1 microscopes configured with widefield fluorescence and AxioCam MRm digital camera or configured with a LSM 700 laser scanning confocal head. Multiple z-stacks were acquired and compressed into a single projected image to better show the cells in their entirety using Zen 2010 software (Zeiss).

Immunoblotting

Western blotting for fractalkine and CX₃CR1 was performed using routine methods previously reported by us [62,64]. Goat anti-mouse fractalkine antibodies (directed against the N-terminal, chemokine domain; catalog no. AF472; R&D Systems) were used at 1:1,500 dilution and

rabbit anti-rat CX₃CR1 antibodies (TP501; Torrey Pines Biolabs) were used at 1:1,000 dilution. The same non-glycosylated, recombinant fractalkine that was neuroprotective against morphine and/or Tat co-exposure (R&D Systems; catalog no. 472-FF/CF) served as a positive control. Proteins were detected via HRP and enhanced chemoluminescence detection (Amersham Biosciences, Fairfield, CT), and quantified using a Kodak 440 Gel Imager. Protein levels were normalized to β-actin (1:3,000; Santa Cruz Biotechnology, Santa Cruz, CA).

ELISA

Fractalkine and TNF-α were assessed by ELISA (R&D Systems) according to the manufacturer's instructions using a Victor-3 platereader (Perkin Elmer Co., Waltham, MA) as previously described [64,70].

Microglial migration

Individual microglia were tracked and images acquired at 20 min intervals, analyzed at 1 h intervals, and the average movement determined during the initial 12 h following experimental treatments. Microglia are readily identified in videos as motile, amoeboid cells with cytoplasmic granularity caused by lysosomes and autophagosomes, and filopodial/lamellipodial cytoplasmic extensions. Microglial identification was verified by immunostaining for Iba-1 at the end of some experiments (Figure 4B). Microglia were randomly selected from within the phase-contrast images at 0 h and the point-to-point distance traveled by each macrophage/microglia was assessed at 1 h intervals, by measuring the linear distance from the last position of the cell body. Because most cells tended not to move in a straight line at a consistent speed, even measurements at relatively frequent 1 h intervals underestimated the total distance traveled by many cells during that time. Despite some irregular movement by individual microglia, the average distance traveled per unit time by all microglia within a particular treatment group was quite reproducible. Approximately 100 microglia were selected in each treatment group per experiment. Cells that moved out of the viewing field were excluded from the determination. Data are presented as the mean migration rate (µm/h) ± SEM from 4 experiments.

Dendrite length estimates

After the time lapse studies were completed at 72 h, cultures were fixed for 15 min with ice-cold Zamboni's fixative, washed in PBS (3 × 5 min), and incubated with anti-rabbit microtubule associated protein-2 (MAP2) antibodies overnight at 4°C (1:200 dilution; Chemicon). MAP2 immunofluorescence was detected using biotinylated secondary antibodies conjugated to peroxidase (Jackson ImmunoResearch, West Grove, PA) and visualized using

diaminobenzidine as a peroxidase substrate. The length of all dendrites within a defined area was estimated by their intersections with calibrated concentric circles using the Scholl procedure [94,95], but with slight modifications for *in vitro* measurements [61]. The mean dendritic length per neuron was calculated from approximately 40-60 neurons sampled per treatment group in each experiment; experiments were repeated at least 3 times and data presented as the mean dendritic length per neuron \pm SEM per experiment.

Statistical analyses

Statistical analyses were done by repeated measures, one-way, and two-way analysis of variance (ANOVA) followed by Duncan's or Bonferroni's post-hoc testing (StatSoft, Statistica, Tulsa, OK).

List of Abbreviations

ADAM: a disintegrin and metalloproteinase; ANOVA: Analysis of variance; RGD domain: Arg-Gly-Asp domain; CCL2 (MCP-1): chemokine (C-C motif) ligand 2 or monocyte chemoattractant protein-2; CCL5 (RANTES): chemokine (C-C motif) ligand 5; ELISA: enzyme-linked immunosorbent assay; ERK: extracellular signal-regulated kinases; $[Ca^{2+}]_o$: extracellular calcium; CX₃CR1: fractalkine receptor; CX₃CL1: fractalkine; GFAP: glial fibrillary acidic protein; iNOS: inducible nitric oxide synthase; IL-1 β : interleukin-1 β ; $[Ca^{2+}]_i$: intracellular calcium; Iba-1: ionized calcium binding adaptor molecule 1; HAND: HIV-associated neurocognitive disorders; HIV-1: human immunodeficiency virus-type 1; MAP-2: microtubule-associated protein type-2; MCP-1: monocyte chemoattractant protein-1; MAPK: mitogen-activated protein kinase; NK cells: natural killer cells; neuroAIDS: neuro-acquired immunodeficiency syndrome; NADPH: nicotinamide adenine dinucleotide phosphate oxidase; PI3K: phosphoinositide 3-kinase; RANTES (CCL5): regulated upon activation, normal T-cell expressed, and secreted; Tat: transactivator of transcription; TNF- α : tumor necrosis factor- α ; TACE (or ADAM 17): TNF- α converting enzyme.

Acknowledgements

We thank Dr. Dan Littman (Skirball Institute, New York University School of Medicine, NY, NY) for making available the *Cx3cr1*^{-/-} mice. The support of grants R21 DA028741, P01 DA19398, and K02 DA027374 from the National Institute on Drug Abuse is gratefully acknowledged.

Author details

¹Department of Pharmacology and Toxicology, Virginia Commonwealth University School of Medicine, Richmond, VA 23298-0613 USA. ²Department of Anatomy and Neurobiology, Virginia Commonwealth University School of Medicine, VA 23298-0709 USA. ³Department of Microbiology and Immunology, Virginia Commonwealth University School of Medicine, VA 23298-0678 USA. ⁴Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, VA 2329-0310 USA. ⁵Cancer Pathophysiology Division, National Cancer Center Research Institute (Tsukiji Campus), 5-1-1, Tsukiji, Chuo-ku, Tokyo 104-0045, JAPAN.

Authors' contributions

MS, JLS, DHC, PEK, and KFH designed the experiments. MS, SZ, NE-H, Y-KH, and MES conducted the experiments. MS, JLS, DHC, PEK, and KFH analyzed and interpreted the data and wrote the manuscript. KFH coordinated the research and supervised the project. All authors have read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 29 October 2010 Accepted: 17 November 2011
Published: 17 November 2011

References

1. Adler MW, Geller EB, Rogers TJ, Henderson EE, Eisenstein TK: **Opioids, receptors, and immunity.** *Adv Exp Med Biol* 1993, **335**:13-20.
2. Kumar R, Orsoni S, Norman L, Verma AS, Tirado G, Giavedoni LD, Staprans S, Miller GM, Buch SJ, Kumar A: **Chronic morphine exposure causes pronounced virus replication in cerebral compartment and accelerated onset of AIDS in SIV/SHIV-infected Indian rhesus macaques.** *Virology* 2006, **354**:192-206.
3. Peterson PK, Sharp BM, Gekker G, Portoghesi PS, Sannerud K, Balfour HH Jr: **Morphine promotes the growth of HIV-1 in human peripheral blood mononuclear cell cocultures.** *AIDS* 1990, **4**:869-873.
4. Donahoe RM, Vlahov D: **Opiates as potential cofactors in progression of HIV-1 infections to AIDS.** *J Neuroimmunol* 1998, **83**:77-87.
5. Carr DJJ, Serou M: **Exogenous and endogenous opioids as biological response modifiers.** *Immunopharmacology* 1995, **31**:59-71.
6. Hauser KF, El-Hage N, Stiene-Martin A, Maragos WF, Nath A, Persidsky Y, Volsky DJ, Knapp PE: **HIV-1 neuropathogenesis: Glial mechanisms revealed through substance abuse.** *J Neurochem* 2007, **100**:567-586.
7. Turchan-Cholewo J, Liu Y, Gartner S, Reid R, Jie C, Peng X, Chen KC, Chauhan A, Haughey N, Cutler R, et al: **Increased vulnerability of ApoE4 neurons to HIV proteins and opiates: protection by diosgenin and L-deprenyl.** *Neurobiol Dis* 2006, **23**:109-119.
8. Hauser KF, El-Hage N, Buch S, Berger JR, Tyor WR, Nath A, Bruce-Keller AJ, Knapp PE: **Molecular targets of opiate drug abuse in neuroAIDS.** *Neurotox Res* 2005, **8**:63-80.
9. Nath A, Hauser KF, Wojna V, Booze RM, Maragos W, Prendergast M, Cass W, Turchan JT: **Molecular basis for interactions of HIV and drugs of abuse.** *J Acquir Immune Defic Syndr* 2002, **31**(Suppl 2):S62-S69.
10. Gurwell JA, Nath A, Sun Q, Zhang J, Martin KM, Chen Y, Hauser KF: **Synergistic neurotoxicity of opioids and human immunodeficiency virus-1 Tat protein in striatal neurons in vitro.** *Neuroscience* 2001, **102**:555-563.
11. Anthony IC, Arango JC, Stephens B, Simmonds P, Bell JE: **The effects of illicit drugs on the HIV infected brain.** *Front Biosci* 2008, **13**:1294-1307.
12. Bell JE, Arango JC, Anthony IC: **Neurobiology of multiple insults: HIV-1-associated brain disorders in those who use illicit drugs.** *J Neuroimmune Pharmacol* 2006, **1**:182-191.
13. Peterson PK, Molitor TW, Chao CC: **The opioid-cytokine connection.** *J Neuroimmunol* 1998, **83**:63-69.
14. Chang SL, Wu GD, Patel NA, Vidal EL, Fiala M: **The effects of interaction between morphine and interleukin-1 on the immune response.** *Adv Exp Med Biol* 1998, **437**:67-72.
15. El-Hage N, Bruce-Keller AJ, Knapp PE, Hauser KF: **CCL5/RANTES gene deletion attenuates opioid-induced increases in glial CCL2/MCP-1 immunoreactivity and activation in HIV-1 Tat exposed mice.** *J Neuroimmune Pharmacol* 2008, **3**:275-285.
16. El-Hage N, Wu G, Wang J, Ambati J, Knapp PE, Reed JL, Bruce-Keller AJ, Hauser KF: **HIV-1 Tat and opiate-induced changes in astrocytes promote chemotaxis of microglia through the expression of MCP-1 and alternative chemokines.** *Glia* 2006, **53**:132-146.
17. El-Hage N, Gurwell JA, Singh IN, Knapp PE, Nath A, Hauser KF: **Synergistic increases in intracellular Ca²⁺, and the release of MCP-1, RANTES, and IL-6 by astrocytes treated with opiates and HIV-1 Tat.** *Glia* 2005, **50**:91-106.
18. Rogers TJ, Peterson PK: **Opioid G protein-coupled receptors: signals at the crossroads of inflammation.** *Trends Immunol* 2003, **24**:116-121.
19. Szabo I, Wetzel MA, Zhang N, Steele AD, Kaminsky DE, Chen C, Liu-Chen LY, Bednar F, Henderson EE, Howard OM, et al: **Selective inactivation of CCR5 and decreased infectivity of R5 HIV-1 strains mediated by opioid-induced heterologous desensitization.** *J Leukoc Biol* 2003, **74**:1074-1082.
20. Parenty G, Appelbe S, Milligan G: **CXCR2 chemokine receptor antagonism enhances DOP opioid receptor function via allosteric regulation of the CXCR2-DOP receptor heterodimer.** *Biochem J* 2008, **412**:245-256.
21. Pello OM, Martinez-Munoz L, Parrillas V, Serrano A, Rodriguez-Frade JM, Toro MJ, Lucas P, Monterrubio M, Martinez A, Mellado M: **Ligand stabilization of CXCR4/delta-opioid receptor heterodimers reveals a mechanism for immune response regulation.** *Eur J Immunol* 2008, **38**:537-549.
22. Chen C, Li J, Bot G, Szabo I, Rogers TJ, Liu-Chen LY: **Heterodimerization and cross-desensitization between the mu-opioid receptor and the chemokine CCR5 receptor.** *Eur J Pharmacol* 2004, **483**:175-186.

23. Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, Greaves DR, Zlotnik A, Schall TJ: **A new class of membrane-bound chemokine with a CX3C motif.** *Nature* 1997, **385**:640-644.
24. Imai T, Hieshima K, Haskell C, Baba M, Nagira M, Nishimura M, Kakizaki M, Takagi S, Nomiyama H, Schall TJ, *et al*: **Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion.** *Cell* 1997, **91**:521-530.
25. Hughes PM, Botham MS, Frenzel S, Mir A, Perry VH: **Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, during acute and chronic inflammation in the rodent CNS.** *Glia* 2002, **37**:314-327.
26. Jung S, Aliberti J, Graemmel P, Sunshine MJ, Kreutzberg GW, Sher A, Littman DR: **Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion.** *Mol Cell Biol* 2000, **20**:4106-4114.
27. Rossi DL, Hardiman G, Copeland NG, Gilbert DJ, Jenkins N, Zlotnik A, Bazan JF: **Cloning and characterization of a new type of mouse chemokine.** *Genomics* 1998, **47**:163-170.
28. Savarin-Vuillat C, Ransohoff RM: **Chemokines and chemokine receptors in neurological disease: raise, retain, or reduce?** *Neurotherapeutics* 2007, **4**:590-601.
29. Yang XP, Mattagajasingh S, Su S, Chen G, Cai Z, Fox-Talbot K, Irani K, Becker LC: **Fractalkine upregulates intercellular adhesion molecule-1 in endothelial cells through CX3CR1 and the Jak Stat5 pathway.** *Circ Res* 2007, **101**:1001-1008.
30. Re DB, Przedborski S: **Fractalkine: moving from chemotaxis to neuroprotection.** *Nat Neurosci* 2006, **9**:859-861.
31. Combadiere C, Salzwedel K, Smith ED, Tiffany HL, Berger EA, Murphy PM: **Identification of CX3CR1. A chemotactic receptor for the human CX3C chemokine fractalkine and a fusion coreceptor for HIV-1.** *J Biol Chem* 1998, **273**:23799-23804.
32. Faure S, Meyer L, Costagliola D, Vaneensbergh C, Genin E, Autran B, Delfraissy JF, McDermott DH, Murphy PM, Debre P, *et al*: **Rapid progression to AIDS in HIV+ individuals with a structural variant of the chemokine receptor CX3CR1.** *Science* 2000, **287**:2274-2277.
33. Shimizu N, Tanaka A, Oue A, Mori T, Ohtsuki T, Apichartpiyakul C, Uchiyama H, Nojima Y, Hoshino H: **Broad usage spectrum of G protein-coupled receptors as coreceptors by primary isolates of HIV.** *AIDS* 2009, **27**:761-769.
34. Becker Y: **The spreading of HIV-1 infection in the human organism is caused by fractalkine trafficking of the infected lymphocytes—a review, hypothesis and implications for treatment.** *Virus Genes* 2007, **34**:93-109.
35. Nishiyori A, Minami M, Ohtani Y, Takami S, Yamamoto J, Kawaguchi N, Kume T, Akaike A, Satoh M: **Localization of fractalkine and CX3CR1 mRNAs in rat brain: does fractalkine play a role in signaling from neuron to microglia?** *FEBS Lett* 1998, **429**:167-172.
36. Meucci O, Fatatis A, Simen AA, Miller RJ: **Expression of CX3CR1 chemokine receptors on neurons and their role in neuronal survival.** *Proc Natl Acad Sci (USA)* 2000, **97**:8075-8080.
37. Ransohoff RM, Liu L, Cardona AE: **Chemokines and chemokine receptors: multipurpose players in neuroinflammation.** *Int Rev Neurobiol* 2007, **82**:187-204.
38. Cardona AE, Pioro EP, Sasse ME, Kostenko V, Cardona SM, Dijkstra IM, Huang D, Kidd G, Dombrowski S, Dutta R, *et al*: **Control of microglial neurotoxicity by the fractalkine receptor.** *Nat Neurosci* 2006, **9**:917-924.
39. Tong N, Perry SW, Zhang Q, James HJ, Guo H, Brooks A, Bal H, Kinnear SA, Fine S, Epstein LG, *et al*: **Neuronal fractalkine expression in HIV-1 encephalitis: roles for macrophage recruitment and neuroprotection in the central nervous system.** *J Immunol* 2000, **164**:1333-1339.
40. Fuhrmann M, Bittner T, Jung CK, Burgold S, Page RM, Mitteregger G, Haass C, LaFerla FM, Kretschmar H, Herms J: **Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer's disease.** *Nat Neurosci* 2010, **13**:411-413.
41. Erichsen D, Lopez AL, Peng H, Niemann D, Williams C, Bauer M, Morgello S, Cotter RL, Ryan LA, Ghorpade A, *et al*: **Neuronal injury regulates fractalkine: relevance for HIV-1 associated dementia.** *J Neuroimmunol* 2003, **138**:144-155.
42. Cotter R, Williams C, Ryan L, Erichsen D, Lopez A, Peng H, Zheng J: **Fractalkine (CX3CL1) and brain inflammation: Implications for HIV-1-associated dementia.** *J Neurovirol* 2002, **8**:585-598.
43. Letendre SL, Zheng JC, Kaul M, Yiannoutsos CT, Ellis RJ, Taylor MJ, Marquie-Beck J, Navia B, HIV Neuroimaging Consortium: **Chemokines in cerebrospinal fluid correlate with cerebral metabolite patterns in HIV-infected individuals.** *J Neurovirol* 2011, **17**:63-69.
44. Depoylu C, Eiden LE, Schafer MK, Reinhart TA, Mitsuya H, Schall TJ, Weihe E: **Fractalkine expression in the rhesus monkey brain during lentivirus infection and its control by 6-chloro-2',3'-dideoxyguanosine.** *J Neuropathol Exp Neurol* 2006, **65**:1170-1180.
45. Foussat A, Bouchet-Delbos L, Berrebi D, Durand-Gasseloin I, Coulomb-L'Hermine A, Krzysiek R, Galanaud P, Levy Y, Emilie D: **Deregulation of the expression of the fractalkine/fractalkine receptor complex in HIV-1-infected patients.** *Blood* 2001, **98**:1678-1686.
46. Meucci O, Fatatis A, Simen AA, Bushell TJ, Gray PW, Miller RJ: **Chemokines regulate hippocampal neuronal signaling and gp120 neurotoxicity.** *Proc Natl Acad Sci (USA)* 1998, **95**:14500-14505.
47. Lauro C, Catalano M, Trettel F, Mainiero F, Ciotti MT, Eusebi F, Limatola C: **The chemokine CX3CL1 reduces migration and increases adhesion of neurons with mechanisms dependent on the beta1 integrin subunit.** *J Immunol* 2006, **177**:7599-7606.
48. Brake DA, Debouck C, Biesecker G: **Identification of an Arg-Gly-Asp (RGD) cell adhesion site in human immunodeficiency virus type 1 transactivation protein, tat.** *J Cell Biol* 1990, **111**:1275-1281.
49. Barillari G, Gendelman R, Gallo RC, Ensoli B: **The Tat protein of HIV, a growth factor for AIDS Kaposi sarcoma and cytokine activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence.** *Proc Natl Acad Sci (USA)* 1993, **90**:7941-7945.
50. Toschi E, Bacigalupo I, Strippoli R, Cereseto A, Falchi M, Chiozzini C, Nappi F, Sgadari C, Barillari G, Mainiero F, *et al*: **HIV-1 Tat Regulates Endothelial Cell Cycle Progression via Activation of the Ras/ERK MAPK Signaling Pathway.** *Mol Biol Cell* 2006, **17**:1985-1994.
51. Vogel BE, Lee S, Hildebrand A, Craig W, Pierschbacher MD, Wong-Stall F, Ruoslahti E: **A novel integrin specificity exemplified by binding of the $\alpha v \beta 5$ integrin to the basic domain of the HIV Tat protein and vitronectin.** *J Cell Biol* 1993, **121**:461-468.
52. Chen X, Geller EB, Rogers TJ, Adler MW: **The chemokine CX3CL1/fractalkine interferes with the antinociceptive effect induced by opioid agonists in the periaqueductal grey of rats.** *Brain Res* 2007, **1153**:52-57.
53. Johnston IN, Milligan ED, Wieseler-Frank J, Frank MG, Zapata V, Campisi J, Langer S, Martin D, Green P, Fleshner M, *et al*: **A role for proinflammatory cytokines and fractalkine in analgesia, tolerance, and subsequent pain facilitation induced by chronic intrathecal morphine.** *J Neurosci* 2004, **24**:7353-7365.
54. Sheng WS, Hu S, Ni HT, Rock RB, Peterson PK: **WIN55,212-2 Inhibits Production of CX3CL1 by Human Astrocytes: Involvement of p38 MAP Kinase.** *J Neuroimmune Pharmacol* 2009, **4**:244-248.
55. Thomas DM, Francescutti-Verbeem DM, Kuhn DM: **Methamphetamine-induced neurotoxicity and microglial activation are not mediated by fractalkine receptor signaling.** *J Neurochem* 2008, **106**:696-705.
56. LINDIA JA, McGOWAN E, JOCHNOWITZ N, ABBADIE C: **Induction of CX3CL1 expression in astrocytes and CX3CR1 in microglia in the spinal cord of a rat model of neuropathic pain.** *J Pain* 2005, **6**:434-438.
57. Garton KJ, Gough PJ, Blobel CP, Murphy G, Greaves DR, Dempsey PJ, Raines EW: **Tumor necrosis factor- α -converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1).** *J Biol Chem* 2001, **276**:37993-38001.
58. Croitoru-Lamoury J, Guillemin GJ, Dormont D, Brew BJ: **Quinolinic acid up-regulates chemokine production and chemokine receptor expression in astrocytes.** *Adv Exp Med Biol* 2003, **527**:37-45.
59. Cook A, Hippensteel R, Shimizu S, Nicolai J, Fatatis A, Meucci O: **Interactions between chemokines: regulation of fractalkine/CX3CL1 homeostasis by SDF/CXCL12 in cortical neurons.** *J Biol Chem* 2010, **285**:10563-10571.
60. Zou S, Fitting S, Hahn YK, Welch SP, El-Hage N, Hauser KF, Knapp PE: **Morphine potentiates neurodegenerative effects of HIV-1 Tat through actions at μ -opioid receptor-expressing glia.** *Brain* 2011.
61. Singh IN, El-Hage N, Campbell ME, Lutz SE, Knapp PE, Nath A, Hauser KF: **Differential involvement of p38 and JNK MAP kinases in HIV-1 Tat and gp120-induced apoptosis and neurite degeneration in striatal neurons.** *Neuroscience* 2005, **135**:781-790.
62. Singh IN, Goody RJ, Dean C, Ahmad NM, Lutz SE, Knapp PE, Nath A, Hauser KF: **Apoptotic death of striatal neurons induced by HIV-1 Tat and**

- gp120: differential involvement of caspase-3 and endonuclease G. *J Neurovirol* 2004, **10**:141-151.
63. Zou S, El-Hage N, Podhaizer EM, Knapp PE, Hauser KF: **PTEN gene silencing prevents HIV-1 gp120_{IIIB}-induced degeneration of striatal neurons.** *J Neurovirol* 2011, **17**:41-49.
64. Bakalkin G, Watanabe H, Jezierska J, Depoorter C, Verschuuren-Bemelmans C, Bazov I, Artemenko KA, Yakovleva T, Dooijes D, *et al*: **Prodynorphin mutations cause the neurodegenerative disorder spinocerebellar ataxia type 23.** *Am J Hum Genet* 2010, **87**:593-603.
65. Friedl P: **Prespecification and plasticity: shifting mechanisms of cell migration.** *Curr Opin Cell Biol* 2004, **16**:14-23.
66. Inoue K: **Purinergic systems in microglia.** *Cell Mol Life Sci* 2008, **65**:3074-3080.
67. Horvath RJ, Deleo JA: **Morphine enhances microglial migration through modulation of P2X4 receptor signaling.** *J Neurosci* 2009, **29**:998-1005.
68. Luo Y, Berman MA, Abromson-Leeman SR, Dorf ME: **Tumor necrosis factor is required for RANTES-induced astrocyte monocyte chemoattractant protein-1 production.** *Glia* 2003, **43**:119-127.
69. Benveniste EN, Benos DJ: **TNF-alpha- and IFN-gamma-mediated signal transduction pathways: effects on glial cell gene expression and function.** *FASEB J* 1995, **9**:1577-1584.
70. El-Hage N, Bruce-Keller AJ, Yakovleva T, Bakalkin G, Knapp PE, Hauser KF: **Morphine exacerbates HIV-1 Tat-induced cytokine production in astrocytes through convergent effects on [Ca²⁺]_i, NF-kB trafficking and transcription.** *PLoS ONE* 2008, **3**:e4093.
71. Heinisch S, Palma J, Kirby LG: **Interactions between chemokine and mu-opioid receptors: anatomical findings and electrophysiological studies in the rat periaqueductal grey.** *Brain Behav Immun* 2011, **25**:360-372.
72. Shan S, Hong-Min T, Yi F, Jun-Peng G, Yue F, Yan-Hong T, Yun-Ke Y, Wen-Wei L, Xiang-Yu W, Jun M, *et al*: **New evidences for fractalkine/CX3CL1 involved in substantia nigral microglial activation and behavioral changes in a rat model of Parkinson's disease.** *Neurobiol Aging* 2011, **32**:443-458.
73. Paolicelli RC, Bolasco G, Pagani F, Maggi L, Scianni M, Panzanelli P, Giustetto M, Ferreira TA, Guiducci E, Dumas L, *et al*: **Synaptic pruning by microglia is necessary for normal brain development.** *Science* 2011, **333**:1456-1458.
74. Hundhausen C, Misztela D, Berkhout TA, Broadway N, Saftig P, Reiss K, Hartmann D, Fahrenholz F, Postina R, Matthews V, *et al*: **The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion.** *Blood* 2003, **102**:1186-1195.
75. Weskamp G, Ford JW, Sturgill J, Martin S, Docherty AJ, Swendeman S, Broadway N, Hartmann D, Saftig P, Umland S, *et al*: **ADAM10 is a principal 'sheddease' of the low-affinity immunoglobulin E receptor CD23.** *Nat Immunol* 2006, **7**:1293-1298.
76. Hundhausen C, Schulte A, Schulz B, Andrzejewski MG, Schwarz N, von HP, Winter U, Paliga K, Reiss K, Saftig P, *et al*: **Regulated shedding of transmembrane chemokines by the disintegrin and metalloproteinase 10 facilitates detachment of adherent leukocytes.** *J Immunol* 2007, **178**:8064-8072.
77. Tsubota K, Nishiyama T, Mishima K, Inoue H, Doi T, Hattori Y, Kodama T, Higuchi A, Hayashi Y, Saito I: **The role of fractalkine as an accelerating factor on the autoimmune exocrinopathy in mice.** *Invest Ophthalmol Vis Sci* 2009, **50**:4753-4760.
78. Wildenberg ME, van Helden-Meeuwssen CG, Drexhage HA, Versnel MA: **Altered fractalkine cleavage potentially promotes local inflammation in NOD salivary gland.** *Arthritis Res Ther* 2008, **10**:R69.
79. Yang XP, Mattagajasingh S, Su S, Chen G, Cai Z, Fox-Talbot K, Irani K, Becker LC: **Fractalkine upregulates intercellular adhesion molecule-1 in endothelial cells through CX3CR1 and the Jak Stat5 pathway.** *Circ Res* 2007, **101**:1001-1008.
80. Garin A, Tarantino N, Faure S, Daoudi M, Lecureuil C, Bourdais A, Debre P, Deterre P, Combadiere C: **Two novel fully functional isoforms of CX3CR1 are potent HIV coreceptors.** *J Immunol* 2003, **171**:5305-5312.
81. Block ML, Zecca L, Hong JS: **Microglia-mediated neurotoxicity: uncovering the molecular mechanisms.** *Nat Rev Neurosci* 2007, **8**:57-69.
82. Cabral GA, Raborn ES, Griffin L, Dennis J, Marciano-Cabral F: **CB2 receptors in the brain: role in central immune function.** *Br J Pharmacol* 2008, **153**:240-251.
83. Carson MJ, Doose JM, Melchior B, Schmid CD, Ploix CC: **CNS immune privilege: hiding in plain sight.** *Immunol Rev* 2006, **213**:48-65.
84. Gonzalez-Scarano F, Martin-Garcia J: **The neuropathogenesis of AIDS.** *Nat Rev Immunol* 2005, **5**:69-81.
85. Gupta S, Knight AG, Gupta S, Knapp PE, Hauser KF, Keller JN, Bruce-Keller AJ: **HIV-Tat elicits microglial glutamate release: role of NAPDH oxidase and the cystine-glutamate antiporter.** *Neurosci Lett* 2010, **485**:233-236.
86. Eugenin EA, Osiecki K, Lopez L, Goldstein H, Calderon TM, Berman JW: **CCL2/monocyte chemoattractant protein-1 mediates enhanced transmigration of human immunodeficiency virus (HIV)-infected leukocytes across the blood-brain barrier: a potential mechanism of HIV-CNS invasion and NeuroAIDS.** *J Neurosci* 2006, **26**:1098-1106.
87. Bhaskar K, Konerth M, Kokiko-Cochran ON, Cardona A, Ransohoff RM, Lamb BT: **Regulation of tau pathology by the microglial fractalkine receptor.** *Neuron* 2010, **68**:19-31.
88. Zhuang ZY, Kawasaki Y, Tan PH, Wen YR, Huang J, Ji RR: **Role of the CX3CR1/p38 MAPK pathway in spinal microglia for the development of neuropathic pain following nerve injury-induced cleavage of fractalkine.** *Brain Behav Immun* 2007, **21**:642-651.
89. Hulshof S, van Haastert ES, Kuipers HF, van den Elsen PJ, De Groot CJ, vand V, Ravid R, Biber K: **CX3CL1 and CX3CR1 expression in human brain tissue: noninflammatory control versus multiple sclerosis.** *J Neuropathol Exp Neurol* 2003, **62**:899-907.
90. Yoshida H, Imaizumi T, Fujimoto K, Matsuo N, Kimura K, Cui X, Matsumiya T, Tanji K, Shibata T, Tamo W, *et al*: **Synergistic stimulation, by tumor necrosis factor-alpha and interferon-gamma, of fractalkine expression in human astrocytes.** *Neurosci Lett* 2001, **303**:132-136.
91. Denes A, Ferenczi S, Halasz J, Kornyei Z, Kovacs KJ: **Role of CX3CR1 (fractalkine receptor) in brain damage and inflammation induced by focal cerebral ischemia in mouse.** *J Cereb Blood Flow Metab* 2008, **28**:1707-1721.
92. Conant K, Garzino-Demo A, Nath A, McArthur JC, Halliday W, Power C, Gallo RC, Major EO: **Induction of monocyte chemoattractant protein-1 in HIV-1 Tat-stimulated astrocytes and elevation in AIDS dementia.** *Proc Natl Acad Sci (USA)* 1998, **95**:3117-3121.
93. Bruce-Keller AJ, Turchan-Cholewo J, Smart EJ, Guerin T, Chauhan A, Reid R, Xu R, Nath A, Knapp PE, Hauser KF: **Morphine causes rapid increases in glial activation and neuronal injury in the striatum of inducible HIV-1 Tat transgenic mice.** *Glia* 2008, **56**:1414-1427.
94. Sholl DA: **Dendritic organization in the neurons of the visual and motor cortices of the cat.** *J Anat (London)* 1953, **87**:387-407.
95. Hauser KF, McLaughlin PJ, Zagon IS: **Endogenous opioid systems and the regulation of dendritic growth and spine formation.** *J Comp Neurol* 1989, **281**:13-22.

doi:10.1186/1750-1326-6-78

Cite this article as: Suzuki *et al*: Fractalkine/CX₃CL1 protects striatal neurons from synergistic morphine and HIV-1 Tat-induced dendritic losses and death. *Molecular Neurodegeneration* 2011 **6**:78.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

